<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134502">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01928979</url>
  </required_header>
  <id_info>
    <org_study_id>16677</org_study_id>
    <secondary_id>NN1301</secondary_id>
    <nct_id>NCT01928979</nct_id>
  </id_info>
  <brief_title>Retrospective Registry Providing Baseline Data on the Outcome of Left Atrial (LA) or LA Appendage (LAA) Thrombus in Patients With Nonvalvular Atrial Fibrillation (AF) or Atrial Flutter After Standard of Care (SoC) Anticoagulant Therapy</brief_title>
  <acronym>CLOT-AF</acronym>
  <official_title>Retrospective Registry Providing Baseline Data on the Outcome of Left Atrial (LA) or LA Appendage (LAA) Thrombus in Patients With Nonvalvular Atrial Fibrillation (AF) or Atrial Flutter After Standard of Care (SoC) Anticoagulant Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Bulgaria: Ethics committee</authority>
    <authority>Bulgaria: Ministry of Health</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>France: Conseil National de l'Ordre des Médecins</authority>
    <authority>France: Direction Générale de la Santé</authority>
    <authority>France: French Data Protection Authority</authority>
    <authority>France: Haute Autorité de Santé Transparency Commission</authority>
    <authority>France: Institutional Ethical Committee</authority>
    <authority>France: Ministry of Health</authority>
    <authority>France: National Consultative Ethics Committee for Health and Life Sciences</authority>
    <authority>France: The Commission nationale de l’informatique et des libertés</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Germany: Federal Ministry of Education and Research</authority>
    <authority>Germany: Federal Ministry of Food, Agriculture and Consumer Protection</authority>
    <authority>Germany: Federal Office for Radiation Protection</authority>
    <authority>Germany: German Institute of Medical Documentation and Information</authority>
    <authority>Germany: Ministry of Health</authority>
    <authority>Germany: Ministry of Work, Health and Social Affairs in North Rhine-Westph</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Germany: The Bavarian State Ministry of the Environment and Public Health</authority>
    <authority>Poland: Ethics Committee</authority>
    <authority>Poland: Ministry of Health</authority>
    <authority>Poland: Ministry of Science and Higher Education</authority>
    <authority>Poland: National Institute of Medicines</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Poland: The Central Register of Clinical Trials</authority>
    <authority>Russia: Ethics Committee</authority>
    <authority>Russia: FSI Scientific Center of Expertise of Medical Application</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Russia: Pharmacological Committee, Ministry of Health</authority>
    <authority>Turkey: Ethics Committee</authority>
    <authority>Turkey: Ministry of Health</authority>
    <authority>Ukraine: Ethics Committee</authority>
    <authority>Ukraine: Ministry of Health</authority>
    <authority>Ukraine: State Pharmacological Center - Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thrombus outcome data will be collected retrospectively during 2011-2012 as a historical
      baseline of SoC with oral VKA (Vitamin K Antagonist(s) for the treatment of patients with
      nonvalvular AF or atrial flutter documented with LA/ LAA thrombi on transesophag-eal
      echocardiography (TEE).

      The study is a company-sponsored, global, multi-center, retrospective, non-interventional
      study. Patients who suffered from hemodynamically stable nonvalvular AF or atrial flutter
      and had a diagnosed LA/ LAA thrombus between January 1st, 2011 and December 31st, 2012 will
      be identified through screening and review of medical records and included in the registry.
      Retrospective patient data will be collected from May 2nd, 2013 to May 2nd, 2014. The
      observation of each patient will cover the period from the diagnosis of an LA/ LAA thrombus
      until the end-of-treatment TEE following the 3-12 week SoC anticoagulation (AC) therapy. If
      no end-of-treatment TEE has been performed during 3-12 weeks of AC therapy, the
      observational period will end at 12 weeks after diagnosis at the latest. If more than one
      TEE was performed during treatment, the thrombus outcome will be collected from the last TEE
      performed within 12 weeks of treatment start.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Thrombus resolution (completely disappeared) rate confirmed on TEE.</measure>
    <time_frame>after 3-12 weeks of SoC treatment or lost to follow up, whichever is later</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stroke or non central nervous system (CNS)  systemic thromboembolism rate</measure>
    <time_frame>after 3-12 weeks of SoC treatment or lost to follow up, whichever is later</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All bleeding (major, non-major, unknown severity) rates</measure>
    <time_frame>after 3-12 weeks of SoC treatment or lost to follow up, whichever is later</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no drug</intervention_name>
    <description>Patients who suffered from hemodynamically stable nonvalvular AF or atrial flutter and had a diagnosed LA/ LAA thrombus between January 1st, 2011 and December 31st, 2012</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who suffered from hemodynamically stable nonvalvular AF or atrial flutter and had
        a diagnosed LA/ LAA thrombus between January 1st, 2011 and December 31st, 2012.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women age ≥ 18 years at data recording

          -  Hemodynamically stable nonvalvular AF or atrial flutter

          -  Documented LA/ LA thrombus on TEE

        Exclusion Criteria:

          -  Valvular AF ( ESC 2012 definition)

          -  History of cardiac thrombus confirmed on TEE

          -  Intracardiac tumors, e.g. atrial myxoma

          -  Active endocarditis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayerhealthcare.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <zip>115093</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <zip>34846</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Turkey</country>
    <country>Ukraine</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>August 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LA/LAA Thrombus</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Observation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
